2024-10-05 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison:**

Eli Lilly and Co. (LLY) has significantly outperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return of 855.92% compared to VOO's 131.45%. This leads to a substantial divergence of 724.47, which is 89.98% of the maximum historical divergence. This indicates that LLY has consistently outpaced the market, but its current position is 10% below its peak outperformance.

**2. Recent Price Movement:**

* **Closing Price:** $891.07
* **5-Day Moving Average:** $890.21
* **20-Day Moving Average:** $909.19
* **60-Day Moving Average:** $897.04

LLY's price is currently trading below its 20-day and 60-day moving averages, suggesting potential downward pressure. However, the 5-day moving average indicates short-term stability.

**3. Technical Indicators:**

* **RSI:** 30.77: This value suggests that the stock is currently in oversold territory, potentially signaling a buying opportunity.
* **PPO:** -0.54: A negative PPO indicates that the stock's price momentum is declining.
* **Delta_Previous_Relative_Divergence:** -8.43: This negative value indicates a recent decline in relative divergence, suggesting a potential shift towards weaker relative performance.
* **Expected Return:** 6.25%: This represents the potential maximum 5-year expected return, exceeding S&P 500 (VOO) performance. 

**4. Recent Earnings and Outlook:**

**Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings for the quarter ending August 8th, 2024, exceeded analysts' expectations by $0.29, demonstrating strong performance. This continued growth suggests that the company remains in a healthy position.

**5. News and Recent Issues:**

* **Recent Market Outlook:** LLY is currently facing potential downward pressure due to recent price action, but the company's strong earnings and promising pipeline suggest a potential for future growth.
* **Analyst Opinions:** Analysts remain optimistic about LLY's long-term prospects, with many rating the stock as a "buy" or "strong buy."
* **Performance Highlights:**  LLY's successful development of new drug therapies, especially in the areas of diabetes and oncology, has significantly contributed to its strong performance. 

**6. Overall Analysis:**

Eli Lilly and Co. (LLY) has consistently outperformed the S&P 500, demonstrating a strong track record of growth and profitability. While recent price action suggests potential downward pressure, the company's impressive earnings, promising pipeline, and positive analyst sentiment indicate a strong foundation for future success. However, investors should closely monitor the stock's price movement and technical indicators for potential shifts in momentum. The oversold RSI and recent decline in relative divergence suggest potential buying opportunities, but caution is advised due to the stock's current price movement. The long-term outlook for LLY remains positive, making it a potentially attractive investment for investors seeking long-term growth.

**7. Summary:**

LLY has consistently outperformed the market, achieving impressive returns. Recent earnings indicate continued growth and strong performance. While the stock may experience some downward pressure, analysts remain optimistic about its future prospects. The stock's current position suggests potential buying opportunities, but investors should closely monitor its price action and technical indicators. 
